Terumo Acquires Quirem Medical to Enhance Its Interventional Oncology Field
Under the terms of the agreement, Terumo acquired 80.1% of the shares of Quirem Medical.
- Under the terms of the agreement, Terumo acquired 80.1% of the shares of Quirem Medical.
- This is over and above its current share position of 19.9%, making Quirem Medical now a wholly owned subsidiary of Terumo.
- Quirem Medical has developed and manufactures QuiremSpheres, the only commercially available microspheres containing the radioactive isotope Holmium-166.
- The global interventional oncology market value is more than USD 1 billion, which is a rapidly growing field with a CAGR of 7%.